Posts

Merck ends development of ArQule’s blood cancer drug

Merck has discontinued development of nemtabrutinib (also known as MK-1026 and formerly ARQ 531), an experimental oral BTK inhibitor for blood cancers. The decision followed a review of the Phase 3 BELLWAVE-011 trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). An independent monitoring committee concluded that the drug’s potential benefits might not outweigh its risks; Merck said its own review confirmed the concern. Merck is also ending the related Phase 3 trials BELLWAVE-008 and BELLWAVE-010, bringing the broader BELLWAVE program to a halt. The company has not publicly detailed the specific data behind the benefit-risk assessment. Nemtabrutinib was the centerpiece of Merck’s roughly $2.7 billion acquisition of ArQule, announced in 2019. The drug’s prospects had faded amid delays and competition from other BTK inhibitors. Sources: Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns Merck axes $2.7B BTK inhibitor pro...

FDA rejects Summit’s ivonescimab application, citing modest benefit and added risks

Pfizer enters in vivo CAR-T with up to $2.6 billion Starna deal

GSK wins FDA approval for second Nuvalent lung cancer drug

CTAD 2026: Biogen and AriBio report signals of slower cognitive decline

Marrow raises $173 million to develop an siRNA approach for sickle cell disease

SELLAS reports Phase 3 survival benefit for investigational AML vaccine

Three takeaways from Isomorphic Labs’ historic $5B raise

White House withdraws Heidi Overton’s FDA nomination

Pfizer licenses Starna’s early-stage in vivo CAR-T programs

Novartis previews hematology and breast cancer data at ASH and SABCS

Siemens Healthineers and Sana Kliniken launch AI collaboration

Cradle platform use expands across argenx antibody discovery programs